TREATMENT OPTIMISATION: Edited by David H. Brown Ripin, Charles W. Flexner and Ben PlumleyAn overview of the antiretroviral marketCamponeschi, Geannan; Fast, Jessica; Gauval, Marianne; Guerra, Katherine; Moore, Meredith; Ravinutala, Siddharth; Ripin, David; Shepel, VadimAuthor Information Clinton Health Access Initiative, Boston, Massachusetts, USA Correspondence to David Ripin, Clinton Health Access Initiative, 383 Dorchester Avenue, Suite 400, Boston, MA 02127, USA. Tel: +1 617 774 0110; e-mail: [email protected] Current Opinion in HIV and AIDS: November 2013 - Volume 8 - Issue 6 - p 535-543 doi: 10.1097/COH.0000000000000012 Buy Metrics Abstract Purpose of review An understanding of the current state of the antiretroviral marketplace is an important context in which to consider drug optimization work. Recent findings The antiretroviral marketplace has undergone a remarkable evolution over the past 11 years, expanding from serving less than 300 000 patients in low and middle-income countries in 2002 to almost 10 million patients today. In addition to dramatic growth, a steady and rapid improvement in the drugs and drug regimens used to treat patients has characterized a rapidly changing market. Summary The antiretroviral marketplace has been characterized by rapid growth and a succession of improving drugs and regimens over the past 11 years. The dynamic and innovative marketplace provides a strong platform from which to introduce new, optimized drugs and regimens to better serve patients’ health needs. © 2013 Lippincott Williams & Wilkins, Inc.